8-K: Surmodics Q3 Results: Pounce & IVD Growth Amidst Merger Fight

Surmodics reports mixed third-quarter fiscal 2025 financial results, with growth in Pounce Thrombectomy and IVD segments offset by declines in SurVeil DCB revenue, while updating full-year guidance amidst ongoing FTC merger litigation.

Summary

• Total revenue for the third quarter of fiscal 2025 was $29.6 million, a 3% decrease year-over-year.
• Excluding SurVeil DCB license fee revenue, total revenue increased by 1% year-over-year to $29.6 million.
• GAAP net loss improved to $(5.3) million, compared to $(7.6) million in the prior-year period.
• Adjusted EBITDA increased to $3.4 million, up from $1.6 million in the prior-year period.
• Medical Device revenue decreased by 5% to $22.2 million, primarily due to a $1.7 million decrease in SurVeil DCB product sales.
• Pounce Thrombectomy Platform sales grew by 35% year-over-year.
• In Vitro Diagnostics (IVD) revenue increased by 6% to $7.4 million, driven by broad-based growth.
• Product gross margin decreased to 48.8% from 51.9%, mainly due to a $1.0 million decline in SurVeil DCB product gross profit.
• Operating costs and expenses, excluding product costs, decreased by $1.0 million to $26.2 million, partly due to a $2.2 million reduction in R&D expense, including a $1.1 million refund from TRANSCEND clinical trials.
• Merger-related charges increased to $5.3 million in Q3 FY25 from $2.9 million in Q3 FY24.
• Fiscal year 2025 total revenue guidance was raised to a range of $116.5 million to $118.5 million.
• Fiscal year 2025 Non-GAAP net loss guidance was improved to a range of $(0.35) to $(0.20) per diluted share.
• The company expects SurVeil DCB license fee revenue to decrease by $3.6 million and product revenue by approximately $7.5 million in fiscal 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While total revenue declined and GAAP net loss guidance worsened due to merger costs, the company showed strong growth in key product lines (Pounce, IVD), improved non-GAAP profitability, and raised its revenue guidance. The primary negative overhang is the uncertainty and cost associated with the FTC's challenge to the pending acquisition, which is a significant external factor.

Positives

• GAAP net loss improved significantly to $(5.3) million from $(7.6) million in the prior-year period.
• Adjusted EBITDA more than doubled to $3.4 million from $1.6 million year-over-year.
• Pounce Thrombectomy Platform sales demonstrated strong growth of 35% year-over-year.
• In Vitro Diagnostics (IVD) segment showed robust growth of 6% year-over-year across all product lines.
• Medical Device R&D and other revenue increased by 37%, reflecting strong customer demand.
• Operating costs and expenses, excluding product costs, decreased by $1.0 million, partly due to a $1.1 million refund from TRANSCEND clinical trials.
• The company successfully launched the Pounce XL Thrombectomy System, expanding its clot removal capabilities.
• Publication of the TRANSCEND clinical trial demonstrated SurVeil DCB's non-inferiority for safety and efficacy with a lower drug dose.
• Expanded the pipeline of device applications for Preside hydrophilic coatings to include all core vascular segments (neuro, coronary, peripheral, structural heart).
• First customer began early commercialization of a device coated with Preside following FDA 510(k) clearance.
• Fiscal year 2025 total revenue guidance was raised to $116.5 million $118.5 million from previous guidance of $114 million $117 million.
• Fiscal year 2025 Non-GAAP net loss guidance was improved to $(0.35) $(0.20) per diluted share from previous guidance of $(0.62) $(0.42) per diluted share.

Negatives

• Total revenue decreased by 3% year-over-year to $29.6 million.
• Medical Device revenue decreased by 5% to $22.2 million.
• SurVeil DCB license fee revenue was $0.0 million, down from $1.1 million in the prior-year period, due to completion of the TRANSCEND clinical trial.
• SurVeil DCB product sales revenue decreased by $1.7 million year-over-year, driven by lower demand from Abbott.
• Product gross profit decreased by 10% to $8.2 million.
• Product gross margin declined to 48.8% from 51.9%, primarily due to under absorption and production inefficiencies related to SurVeil DCB.
• Merger-related charges significantly increased to $5.3 million in Q3 FY25 from $2.9 million in Q3 FY24.
• GAAP net loss guidance for fiscal year 2025 worsened to a range of $(1.70) to $(1.55) per diluted share from prior guidance of $(1.60) to $(1.40) per diluted share.
• The company continues to experience a headwind from lower SurVeil DCB revenue, with expected decreases of $3.6 million in license fees and approximately $7.5 million in product revenue for fiscal 2025.

Risks

• The proposed acquisition by GTCR may not be consummated due to various factors, including failure to secure regulatory approvals or other conditions not being satisfied.
• The Federal Trade Commission (FTC) has issued an administrative complaint and is seeking to block the merger in federal court, creating significant uncertainty.
• If the merger agreement is terminated, the company's stock price may decline significantly.
• The company may be required to pay a termination fee of $20.38 million to the buyer if the merger agreement is terminated under certain circumstances.
• The announcement or pendency of the merger may adversely affect the company's business, operating results, stock price, ability to retain/recruit key employees, and business relationships.
• The merger agreement places limitations on the company's ability to operate its business, return capital to shareholders, or engage in alternative transactions.
• There are ongoing and potential future litigation and legal proceedings, including those related to the merger, which could incur unexpected costs, liabilities, or delays.
• The company's ability to successfully commercialize its SurVeil DCB, Sundance DCB, and other proprietary products, including realizing the full benefits of the Abbott agreement, is uncertain.
• Reliance on third parties (customers and licensees) means their failure to successfully develop, obtain regulatory approval for, market, and sell products incorporating Surmodics' technologies could negatively impact results.
• Possible adverse market conditions and impacts on cash flows could occur.
• The ability to successfully and profitably produce and commercialize vascular intervention products is a risk.
• Supply chain constraints could impact operations.
• There is a risk that operating expenses may not be effective in generating profitable revenues.
• The company's exposure to tariff impacts related to its supply chain and customer sales is difficult to quantify and unpredictable.

Future Outlook

The company is raising its fiscal year 2025 total revenue guidance to a range of $116.5 million to $118.5 million and improving its Non-GAAP net loss guidance to $(0.35) to $(0.20) per diluted share, reflecting strong third-quarter performance in certain areas. However, it anticipates continued impact from lower SurVeil DCB license fee and product revenue, with expected decreases of $3.6 million and approximately $7.5 million, respectively, for the fiscal year. The GAAP net loss guidance for fiscal 2025 has worsened to $(1.70) to $(1.55) per diluted share, largely due to increased merger-related charges of approximately $16.0 million.

Management Comments

• "While our performance in the third quarter remained impacted by lower SurVeil DCB revenue, which decreased $2.8 million year-over-year, this headwind was consistent with our stated expectations, and we achieved broad-based growth across the rest of our business."
• "Most notably, in our Medical Device segment, we delivered 35% growth in Pounce Thrombectomy Platform sales year-over-year, which was coupled with 37% growth in R&D and other revenue, reflecting strong customer demand."
• "In our IVD segment, we were pleased to see strength across our product portfolio, culminating in 6% growth year-over-year."
• "In terms of our strategic priorities, we remain focused on facilitating the long-term growth of our products, controlling expenses across our organization, and completing the pending acquisition of Surmodics."
• "Our team began full commercialization of Pounce XL Thrombectomy during the third quarter, and we have been pleased with the markets response to-date."
• "We also expanded the pipeline of device applications evaluating our Preside hydrophilic coatings to include all core vascular segments of neuro, coronary, peripheral, and structural heart, and saw our first customer begin early commercialization of a device coated with this advanced technology, following the receipt of FDA 510(k) clearance."
• "In tandem, we delivered notable year-over-year reductions in operating costs and expenses during the third quarter, despite $2.5 million of higher merger-related expenses, and improvements in both Net Loss and Adjusted EBITDA."
• "Together with our external advisors, we continue to work diligently to respond to the FTCs administrative complaint and federal court action challenging the proposed merger, with the goal of completing the pending acquisition of Surmodics by an affiliate of GTCR."
• "We are raising our financial guidance today to reflect the strong third quarter performance across many areas of our business, and updated expectations for the balance of the year."
• "Surmodics remains focused on building upon our recent financial and operational accomplishments and driving continued progress with respect to each of our three strategic priorities, as we work to deliver value for our stakeholders."

Industry Context

The medical device and in vitro diagnostics industries are characterized by continuous innovation, regulatory scrutiny, and competitive pressures. Surmodics' focus on specialized coating technologies and vascular intervention devices positions it within high-growth niches. The strong performance of its Pounce Thrombectomy Platform and IVD segment indicates success in addressing specific clinical needs and market demand. However, the decline in SurVeil DCB revenue highlights the challenges of product commercialization and market adoption, especially when relying on distribution partners like Abbott. The ongoing FTC challenge to the GTCR acquisition reflects the increasing regulatory oversight in healthcare M&A, aiming to prevent potential anti-competitive impacts in specialized medical technology markets.

Comparison to Industry Standards

• The TRANSCEND clinical trial demonstrated the SurVeil drug-coated balloon (DCB) is non-inferior to the IN.PACT Admiral DCB for safety and efficacy. The IN.PACT Admiral DCB is a leading product in the femoropopliteal arterial disease market, manufactured by Medtronic, indicating SurVeil's competitive clinical profile despite its lower drug dose.
• The 35% year-over-year growth in Pounce Thrombectomy Platform sales suggests strong market penetration and adoption compared to general market growth rates for thrombectomy devices, which vary but typically see high single-digit to low double-digit growth. Specific comparable companies in the thrombectomy space include Penumbra (with its Indigo System) and Inari Medical (with its FlowTriever and ClotTriever systems), though direct financial comparisons are not provided in the filing.
• The 6% growth in In Vitro Diagnostics (IVD) revenue is a solid performance, aligning with or slightly exceeding the typical growth rates for the broader IVD market, which generally sees mid-single-digit percentage growth driven by demand for diagnostic testing and new technologies.

Legal Proceedings

• On March 6, 2025, the FTC voted to issue an administrative complaint and authorized its staff to seek to block the proposed merger with GTCR in a federal court with a temporary restraining order and a preliminary injunction.
• A hearing in federal court on the temporary restraining order and a preliminary injunction had been scheduled to begin on August 21, 2025.
• The merger remains subject to the successful resolution of the FTC litigation and the conditions of the merger agreement.

Stakeholder Impact

• Shareholders: The pending acquisition by GTCR at $43.00 per share offers a fixed cash return if completed, but the FTC litigation introduces significant uncertainty and risk of the deal falling through, which could lead to a decline in share price. The company's improved non-GAAP results and raised revenue guidance offer some underlying business strength.
• Employees: The pendency of the merger and the FTC challenge may create uncertainty regarding job security and future corporate structure, potentially affecting retention and recruitment.
• Customers: Continued commercialization of new products like Pounce XL and devices with Preside coatings indicates ongoing innovation and product availability. However, lower demand for SurVeil DCB from Abbott suggests potential shifts in product focus or market dynamics for that specific product.
• Suppliers: Supply chain constraints are noted as a risk, which could impact the company's ability to produce and commercialize products.
• Creditors: The company has $5.0 million in outstanding borrowings on its revolving credit facility and $25.0 million on its term loan facility, with access to additional debt capital, indicating a stable but leveraged financial position. The merger's outcome could impact future debt servicing and financing arrangements.

Next Steps

• Continue full commercialization of the Pounce XL Thrombectomy System.
• Further expand the pipeline of device applications for Preside hydrophilic coatings.
• Work diligently with external advisors to respond to the FTC's administrative complaint and federal court action challenging the proposed merger.
• Focus on building upon recent financial and operational accomplishments.
• Drive continued progress with respect to the three strategic priorities: facilitating long-term product growth, controlling expenses, and completing the pending acquisition.
• Await the outcome of the federal court hearing on the temporary restraining order and preliminary injunction regarding the merger, scheduled to begin August 21, 2025.

Key Dates

Recommendation

The stock is currently subject to a pending acquisition by GTCR at $43.00 per share. While the company's underlying business shows positive momentum in key areas like Pounce Thrombectomy and IVD, the significant uncertainty surrounding the FTC's legal challenge to block the merger creates a binary outcome. If the merger proceeds, shareholders will receive the agreed-upon cash price. If the FTC successfully blocks it, the stock price is highly likely to decline significantly from its current levels, reflecting the removal of the acquisition premium and the costs incurred during the process. Given the fixed upside if the deal closes and the substantial downside risk if it fails, a 'hold' recommendation is appropriate for investors who are comfortable with the speculative nature of the merger arbitrage, awaiting the outcome of the FTC litigation. New investors should exercise extreme caution due to the high event risk.

Keywords

Medical Device, In Vitro Diagnostics, Thrombectomy, Drug-Coated Balloon, Hydrophilic Coatings, SEC Filing, Financial Results, Merger, Acquisition, FTC Litigation, SRDX, Surmodics